Compugen Ltd. (CGEN) vs Cartesian Therapeutics, Inc. (RNAC)

Compugen Ltd. and Cartesian Therapeutics, Inc. are both Biotechnology companies. Compugen Ltd. and Cartesian Therapeutics, Inc. are of similar size ($230.6M and $224.5M). Cartesian Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Compugen Ltd. trades at 6.3×. Compugen Ltd. grew revenue faster over the last twelve months: 234.2% against −94.8%. Compugen Ltd. has the higher net margin (47.6% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Compugen Ltd. leads on 12 and Cartesian Therapeutics, Inc. on 4.

Valuation

Metric CGEN RNAC Biotechnology median
P/E 6.26 n/m 7.88
P/S 3.04 123.01 11.47
P/B 2.54 n/m 2.52
Price to free cash flow 5.63 n/m 21.16
EV/EBITDA 3.30 n/m 0.74
EV/Sales 1.35 75.40 10.73
Earnings yield 15.97% (80.03%) (28.84%)
Free cash flow yield 17.78% (36.00%) (23.03%)

Profitability

Metric CGEN RNAC Biotechnology median
Gross margin 86.89% 100.00% 65.16%
Operating margin 40.94% 0.00% 0.00%
Net margin 47.55% 0.00% 0.00%
Free cash flow margin 54.10% 0.00% 0.00%
Return on equity 47.85% 236.88% (57.72%)
Return on assets 23.86% (42.77%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CGEN RNAC Biotechnology median
Revenue growth (TTM) 234.18% (94.81%) 5.64%
EPS growth (last fiscal year) 337.50% (11.80%) —
Revenue growth, 5-year CAGR 105.20% (29.96%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEN RNAC Biotechnology median
Debt to equity 0.00 (0.42) 0.00
Current ratio 5.72 7.48 4.73
Net debt to EBITDA (4.65) 0.89 0.96

Dividend

Metric CGEN RNAC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CGEN RNAC Biotechnology median
Market cap 224.51m 230.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack